Prairie Sky Financial Group LLC Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Prairie Sky Financial Group LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 1.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,811 shares of the company’s stock after selling 76 shares during the period. Johnson & Johnson makes up about 0.4% of Prairie Sky Financial Group LLC’s investment portfolio, making the stock its 28th biggest position. Prairie Sky Financial Group LLC’s holdings in Johnson & Johnson were worth $696,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of JNJ. Fred Alger Management LLC lifted its position in shares of Johnson & Johnson by 6.1% in the 2nd quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock worth $6,280,000 after purchasing an additional 2,488 shares during the period. AQR Capital Management LLC lifted its position in shares of Johnson & Johnson by 38.6% in the 2nd quarter. AQR Capital Management LLC now owns 3,350,292 shares of the company’s stock worth $489,176,000 after purchasing an additional 932,477 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Johnson & Johnson by 5.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 14,374,397 shares of the company’s stock worth $2,100,427,000 after purchasing an additional 754,200 shares during the period. Drucker Wealth 3.0 LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $612,000. Finally, Daymark Wealth Partners LLC raised its stake in shares of Johnson & Johnson by 2.0% during the 2nd quarter. Daymark Wealth Partners LLC now owns 304,204 shares of the company’s stock worth $44,462,000 after acquiring an additional 6,033 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent analyst reports. Guggenheim boosted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday. Barclays reduced their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.06.

Johnson & Johnson Trading Up 0.9 %

Shares of Johnson & Johnson stock opened at $146.58 on Friday. The stock has a market cap of $352.91 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a fifty day moving average price of $148.10 and a 200 day moving average price of $156.05. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $2.29 earnings per share. Equities research analysts predict that Johnson & Johnson will post 9.95 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.